美沙酮与吗啡治疗新生儿戒断综合征的安全性和有效性比较:一项随机临床试验
这项随机双盲意向治疗试验纳入117名需要治疗的新生儿戒断综合征(NAS)足月儿,比较美沙酮与吗啡的短期结局。
要点
- 调整后美沙酮使LOS相对减少14%,LOT相对减少16%。
核心结论
- 在采用基于体重和体征的NAS治疗方案下,美沙酮组婴儿的短期结局优于吗啡组。
- 长期结局的评估正在进行中。
研究设计与样本
- 随机、双盲、意向治疗试验,纳入来自美国8个新生儿单位的足月儿,其母亲孕期接受丁丙诺啡、美沙酮或阿片类药物镇痛。
- 2014年2月9日至2017年3月6日共117名婴儿随机接受美沙酮或吗啡;1名家长撤回知情同意,最终分析116名婴儿(平均胎龄39.1周,平均出生体重3157克,男性58名占50%)。
- 另有多名母亲拒绝随机化但同意数据收集和标准机构治疗,其170名接受吗啡治疗的婴儿作为非随机对照。
主要发现
- 研究婴儿的短期结局优于170名按标准机构方案接受吗啡治疗的非随机婴儿。
关键数值与推荐
- 使用Finnegan新生儿戒断评分系统每4小时评估婴儿,美沙酮或安慰剂每4小时给药,吗啡每4小时给药。
- Finnegan评分持续升高的婴儿接受剂量增加;超过预定阿片剂量的婴儿接受苯巴比妥。
- 当NAS体征被治疗控制时,每12至48小时进行剂量递减,至原始剂量的20%时停止。
临床怎么用
- 对于需要药物治疗的NAS足月儿,在采用基于体重和体征的治疗方案时,可考虑选用美沙酮以缩短住院时间和药物治疗时间。
- 需结合研究站点和母亲阿片类药物类型等背景因素解读疗效差异。
局限性
- 美沙酮组产前香烟暴露多于吗啡组,尽管 demographic 变量和风险因素总体相似。
- 研究仅报告短期结局,长期结局评估仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although opioids are used to treat neonatal abstinence syndrome (NAS), the best pharmacologic treatment has not been established. OBJECTIVE: To compare the safety and efficacy of methadone and morphine in NAS. DESIGN, SETTING, AND PARTICIPANTS: In this randomized, double-blind, intention-to-treat trial, term infants from 8 US newborn units whose mothers received buprenorphine, methadone, or opioids for pain control during pregnancy were eligible. A total of 117 infants were randomized to receive methadone or morphine from February 9, 2014, to March 6, 2017. Mothers who declined randomization could consent to data collection and standard institutional treatment. INTERVENTIONS: Infants were assessed with the Finnegan Neonatal Abstinence Scoring System every 4 hours and treated with methadone or placebo every 4 hours or morphine every 4 hours. Infants with persistently elevated Finnegan scores received dose increases. Infants who exceeded a predetermined opioid dose received phenobarbital. Dose reductions occurred every 12 to 48 hours when signs of NAS were controlled with therapy, stopping at 20% of the original dose. MAIN OUTCOMES AND MEASURES: The primary end point was length of hospital stay (LOS). The secondary end points were LOS attributable to NAS and length of drug treatment (LOT). RESULTS: A total of 183 mothers consented to have their infants in the study; 117 infants required treatment. Because 1 parent withdrew consent, data were analyzed on 116 infants (mean [SD] gestational age, 39.1 [1.1] weeks; mean [SD] birth weight, 3157 [486] g; 58 [50%] male). Demographic variables and risk factors were similar except for more prenatal cigarette exposure in infants who received methadone. Adjusting for study site and maternal opioid type, methadone was associated with decreased mean number of days for LOS by 14% (relative number of days, 0.86; 95% CI, 0.74-1.00; P = .046), corresponding to a difference of 2.9 days; 14% reduction in LOS attributable to NAS (relative number of days, 0.86; 95% CI, 0.77-0.96; P = .01), corresponding to a difference of 2.7 days; and 16% reduction in LOT (relative number of days, 0.84; 95% CI, 0.73-0.97; P = .02), corresponding to a difference of 2.3 days. Methadone was also associated with reduced median LOS (16 vs 20 days, P = .005), LOS attributable to NAS (16 vs 19 days, P = .005), and LOT (11.5 vs 15 days, P = .009). Study infants had better short-term outcomes than 170 nonrandomized infants treated with morphine per standard institutional protocols. CONCLUSIONS AND RELEVANCE: With use of weight- and sign-based treatment for NAS, short-term outcomes were better in infants receiving methadone compared with morphine. Assessment of longer-term outcomes is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01958476.
引用
- Davis JM, Shenberger J, Terrin N, et al. Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2018. PMID: 29913015. doi:10.1001/jamapediatrics.2018.1307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。